Eli Lilly (NYSE:LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination ...

From PBMs to abortion, there are plenty of health policy issues that will vie for the spotlight in 2025. For pharma marketers ...

This could start to bring down the cost of brand-name competitors—here's who may get to use it, and one major difference from ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Last December, the FDA published its final guidance on predetermined change control plans, or PCCPs, with recommendations to ...

In its overview of egg markets last week, the U.S. Department of Agriculture (USDA) said the California benchmark for large ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

The RELIEF ureteral stent, the brainchild of Dr. Lee Ponksy, chairman of UH’s Urology Institute, has been cleared by the U.S.

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...